These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. [Relationship between ATP-binding cassette subfamily B member 1 and cytochrome P450 2C19 polymorphisms and the effect of clopidogrel post percutaneous coronary intervention in patients with acute coronary syndrome]. Zhou CF; Ren YH; Song YQ; Yi J; Han BS; Xue Q; Fu ZH; Li DY Zhonghua Xin Xue Guan Bing Za Zhi; 2016 Apr; 44(4):309-14. PubMed ID: 27112608 [TBL] [Abstract][Full Text] [Related]
3. CYP2C19 LOF and GOF-Guided Antiplatelet Therapy in Patients with Acute Coronary Syndrome: A Cost-Effectiveness Analysis. Jiang M; You JH Cardiovasc Drugs Ther; 2017 Feb; 31(1):39-49. PubMed ID: 27924429 [TBL] [Abstract][Full Text] [Related]
5. Dual Antiplatelet Therapy Guided by CYP2C19 Polymorphisms after Implantation of Second-Generation Drug-Eluting Stents for Management of Acute Coronary Syndrome. Ozawa T; Suda M; Ikegami R; Takano T; Wakasugi T; Yanagawa T; Tanaka K; Ozaki K; Hirono S; Minamino T Int Heart J; 2018 Jan; 59(1):21-26. PubMed ID: 29279531 [TBL] [Abstract][Full Text] [Related]
6. [Effects of clopidogrel resistence and CYP2C19 genotype on the clinical prognosis of patients with acute coronary syndrome undergoing percutaneous coronary intervention]. He CB; Li Q; Ye YC; Zhao XL; Tu CC; Zeng Y Zhonghua Xin Xue Guan Bing Za Zhi; 2020 Sep; 48(9):765-771. PubMed ID: 32957760 [No Abstract] [Full Text] [Related]
7. Genotype-guided antiplatelet therapy compared with conventional therapy for patients with acute coronary syndromes: a systematic review and meta-analysis. Zheng L; Yang C; Xiang L; Hao Z Biomarkers; 2019 Sep; 24(6):517-523. PubMed ID: 31215825 [TBL] [Abstract][Full Text] [Related]
8. [Impact of CYP2C19 genotype and platelet function on clinical outcome in coronary atherosclerotic heart diseases patients received clopidogrel post percutaneous coronary intervention]. Wu Y; Zhang XX; Tian L; Jiang JJ; Xu L; Huang YL; Liu H; Li YS Zhonghua Xin Xue Guan Bing Za Zhi; 2017 May; 45(5):377-385. PubMed ID: 28511321 [No Abstract] [Full Text] [Related]
9. The contribution of genotype-guided selection of P2Y Wu Y; Yu D; Zhang L; Wu Y; Shu B; Ma L; Shi T Eur J Clin Pharmacol; 2023 Sep; 79(9):1249-1259. PubMed ID: 37449992 [TBL] [Abstract][Full Text] [Related]
10. Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial. Wallentin L; James S; Storey RF; Armstrong M; Barratt BJ; Horrow J; Husted S; Katus H; Steg PG; Shah SH; Becker RC; Lancet; 2010 Oct; 376(9749):1320-8. PubMed ID: 20801498 [TBL] [Abstract][Full Text] [Related]
11. The efficacy and safety of CYP2C19 genotype-guided antiplatelet therapy compared with conventional antiplatelet therapy in patients with acute coronary syndrome or undergoing percutaneous coronary intervention: A meta-analysis of randomized controlled trials. Lyu SQ; Yang YM; Zhu J; Wang J; Wu S; Zhang H; Shao XH; Ren JM Platelets; 2020 Nov; 31(8):971-980. PubMed ID: 32546030 [TBL] [Abstract][Full Text] [Related]
12. Clinical Impact of CYP2C19 Genotype on Clopidogrel-Based Antiplatelet Therapy After Percutaneous Coronary Intervention. Lee SH; Jeong YH; Hong D; Choi KH; Lee JM; Park TK; Yang JH; Hahn JY; Choi SH; Gwon HC; Jeong MH; Kim BK; Joo HJ; Chang K; Park Y; Ahn SG; Suh JW; Lee SY; Cho JR; Her AY; Kim HS; Kim MH; Lim DS; Shin ES; Song YB; JACC Cardiovasc Interv; 2023 Apr; 16(7):829-843. PubMed ID: 37045504 [TBL] [Abstract][Full Text] [Related]
14. Impact of gene polymorphisms, platelet reactivity, and the SYNTAX score on 1-year clinical outcomes in patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention: the GEPRESS study. Palmerini T; Calabrò P; Piscione F; De Servi S; Cattaneo M; Maffeo D; Toso A; Bartorelli A; Palmieri C; De Carlo M; Capodanno D; Barozzi C; Tomasi L; Della Riva D; Mariani A; Taglieri N; Reggiani LB; Bianchi R; De Rosa R; Mariani M; Podda G; Généreux P; Stone GW; Angiolillo DJ JACC Cardiovasc Interv; 2014 Oct; 7(10):1117-27. PubMed ID: 25240538 [TBL] [Abstract][Full Text] [Related]
15. CYP2C19 genotype-guided antiplatelet therapy in ST-segment elevation myocardial infarction patients-Rationale and design of the Patient Outcome after primary PCI (POPular) Genetics study. Bergmeijer TO; Janssen PW; Schipper JC; Qaderdan K; Ishak M; Ruitenbeek RS; Asselbergs FW; van 't Hof AW; Dewilde WJ; Spanó F; Herrman JP; Kelder JC; Postma MJ; de Boer A; Deneer VH; ten Berg JM Am Heart J; 2014 Jul; 168(1):16-22.e1. PubMed ID: 24952855 [TBL] [Abstract][Full Text] [Related]
16. Clinical Utility of CYP2C19 Genotyping to Guide Antiplatelet Therapy in Patients With an Acute Coronary Syndrome or Undergoing Percutaneous Coronary Intervention. Klein MD; Williams AK; Lee CR; Stouffer GA Arterioscler Thromb Vasc Biol; 2019 Apr; 39(4):647-652. PubMed ID: 30760018 [TBL] [Abstract][Full Text] [Related]
17. Study design and rationale for Optimal aNtiplatelet pharmacotherapy guided by bedSIDE genetic or functional TESTing in elective percutaneous coronary intervention patients (ONSIDE TEST): a prospective, open-label, randomised parallel-group multicentre trial (NCT01930773). Kołtowski Ł; Aradi D; Huczek Z; Tomaniak M; Sibbing D; Filipiak KJ; Kochman J; Balsam P; Opolski G Kardiol Pol; 2016; 74(4):372-9. PubMed ID: 26365936 [TBL] [Abstract][Full Text] [Related]
18. Clinical outcomes of CYP2C19 genotype-guided antiplatelet therapy: existing evidence and future directions. Klein MD; Lee CR; Stouffer GA Pharmacogenomics; 2018 Aug; 19(13):1039-1046. PubMed ID: 30028231 [TBL] [Abstract][Full Text] [Related]
19. Impact of CYP2C19 genetic testing on provider prescribing patterns for antiplatelet therapy after acute coronary syndromes and percutaneous coronary intervention. Desai NR; Canestaro WJ; Kyrychenko P; Chaplin D; Martell LA; Brennan T; Matlin OS; Choudhry NK Circ Cardiovasc Qual Outcomes; 2013 Nov; 6(6):694-9. PubMed ID: 24192573 [TBL] [Abstract][Full Text] [Related]
20. Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a randomised trial. Wiviott SD; Braunwald E; McCabe CH; Horvath I; Keltai M; Herrman JP; Van de Werf F; Downey WE; Scirica BM; Murphy SA; Antman EM; Lancet; 2008 Apr; 371(9621):1353-63. PubMed ID: 18377975 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]